NEW ORLEANS, March 24 (Reuters) - The drug-coated stent made by Abbott Laboratories Inc. demonstrated superiority over Boston Scientific Corp's top-selling Taxus stent, according to results of a ...
- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding - XIENCE is the most used ...
ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its XIENCE family of stents has received U.S. Food and Drug Administration (FDA) approval for one-month (as short as ...
PARIS, France—Firehawk, a sirolimus-eluting stent featuring abluminal grooves and a biodegradable polymer, matches the safety and efficacy of the Xience everolimus-eluting stent over 2 years of follow ...
WASHINGTON, Oct 22 (Reuters) - An experimental heart device from Abbott Laboratories proved better at cutting the risk of death from heart attacks and other major cardiac events than a rival made by ...
Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels
Abbott Now Offers a 2.25 mm Version of the Market-Leading XIENCE V® Drug Eluting Stent, Which Has Been Studied in More Than 30,000 Patients Worldwide FDA approval of XIENCE nano was supported by ...
NATIONAL HARBOR, MD—At 3 years, the bioresorbable-polymer Orsiro stent maintains an advantage over the durable-polymer Xience, according to new data from the BIOFLOW V study. Compared with PCI ...
September 25, 2009 (San Francisco, California) — With results that back up those of SPIRIT IV, a second randomized controlled trial comparing the Xience V everolimus-eluting stent (Abbott) with a ...
CHICAGO — Ten-year results from the ISAR-TEST 4 trial have shown that new-generation drug-eluting stents are superior to early-generation stents in terms of clinical outcomes, including mortality.
Abbott today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual antiplatelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – ...
- XIENCE stents have 10+ years of clinical data across 120 clinical trials, more than 125,000 patients and 15 million stent¹ implants ABBOTT PARK, Ill., June 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback